VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
UTHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
UTHRUnited Therapeutics Corporation
$577.34$24.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksUTHRFinancials

United Therapeutics Corporation (UTHR) Income Statement

28Y historyFree accessUpdated daily

Revenue growth has slowed to 4.1% in 2026Q3 while operating margin compressed to 37.0% from roughly 48% in mid-2025, suggesting rising R&D (to $279.2M) is absorbing operating leverage.

Income StatementBalance SheetCash FlowRatios

UTHR Income Statement

Annual statement

UTHR Income Statement

United Therapeutics Corporation (UTHR) annual income statement — 28-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98
Sales/Revenue3.19B3.18B2.88B2.33B1.94B1.69B1.48B1.45B1.63B1.73B1.6B1.47B1.29B1.12B916.08M743.18M603.83M369.85M281.5M210.94M159.63M115.92M73.59M53.34M30.12M5.73M2.05M400K100K
Revenue Growth %1.89%10.61%23.63%20.2%14.88%13.63%2.38%-11%-5.65%7.91%9.08%13.76%15.36%21.93%23.26%23.08%63.26%31.39%33.45%32.14%37.71%57.51%37.96%77.09%425.5%179.7%412.31%300%-
Cost of Goods Sold435.4M384.4M309.7M257.5M146.7M122.5M108.1M117.6M198.7M105.7M72.7M69.04M125.88M131.13M119.3M88.9M73.47M45.32M30.07M22.26M17.03M12.31M8.25M6.78M5.46M3.14M1.71M1.4M0
COGS % of Revenue-12.08%10.76%11.06%7.58%7.27%7.29%8.12%12.21%6.13%4.55%4.71%9.77%11.74%13.02%11.96%12.17%12.25%10.68%10.55%10.67%10.62%11.21%12.72%18.11%54.73%83.24%350%-
Gross Profit2.75B2.8B2.57B2.07B1.79B1.56B1.38B1.33B1.43B1.62B1.53B1.4B1.16B985.86M796.78M654.28M530.37M324.53M251.43M188.68M142.6M103.6M65.34M46.56M24.66M2.59M343.47K-1M100K
Gross Margin %86.34%87.92%89.24%88.94%92.42%92.73%92.71%91.88%87.79%93.87%95.45%95.29%90.23%88.26%86.98%88.04%87.83%87.75%89.32%89.45%89.33%89.38%88.79%87.28%81.89%45.27%16.76%-250%100%
Gross Profit Growth %-8.98%24.04%15.67%14.5%13.66%3.31%-6.85%-11.76%6.13%9.26%20.13%17.93%23.73%21.78%23.36%63.43%29.07%33.26%32.31%37.65%58.56%40.34%88.77%850.61%655.39%134.35%-1100%-
Operating Expenses1.43B1.28B1.19B885.1M809.9M1.01B781.6M1.52B623.7M594.7M464.4M697.71M623.84M693.36M375.13M336.5M366.36M298.53M333.49M182.38M113.62M60.71M52.13M58.08M42.67M49.53M81.84M34.4M13.4M
OpEx % of Revenue-40.25%41.38%38.03%41.83%59.75%52.69%104.83%38.32%34.47%29.05%47.6%48.41%62.07%40.95%45.28%60.67%80.72%118.47%86.46%71.18%52.37%70.84%108.89%141.66%864.2%3993.84%8600%13400%
Selling, General & Admin695.5M731.1M638.6M477.1M487M467M423.9M336.2M265.8M330.1M316.8M452.61M381.29M394.01M201.75M156.48M199.6M176.34M94.31M99.03M54.03M24.66M21.53M22.67M15.89M16.94M11.74M5M2.4M
SG&A % of Revenue-22.97%22.19%20.5%25.15%27.71%28.58%23.21%16.33%19.13%19.81%30.88%29.59%35.27%22.02%21.06%33.06%47.68%33.5%46.94%33.85%21.27%29.26%42.49%52.75%295.6%572.7%1250%2400%
Research & Development703.2M550M481M408M322.9M540.1M357.7M1.18B357.9M264.6M147.6M245.1M242.55M299.35M173.39M180.01M166.76M122.19M239.18M83.35M57.57M36.05M30.6M35.42M26.78M32.59M70.19M30.7M11M
R&D % of Revenue-17.28%16.72%17.53%16.68%32.04%24.12%81.63%21.99%15.34%9.23%16.72%18.82%26.8%18.93%24.22%27.62%33.04%84.97%39.51%36.06%31.1%41.58%66.4%88.9%568.6%3425.03%7675%11000%
Other Operating Expenses1000K071.1M00000002.4M157K3.97M635K00000056.05M00000-79.74K-1.3M0
Operating Income1.32B1.52B1.38B1.18B979.7M555.9M593.6M-187.6M805.4M814.9M1.06B699.01M538.8M292.5M421.65M317.78M164M26M-82.06M6.3M28.98M42.89M13.21M-11.53M-18M-46.94M-81.5M-35.4M-13.3M
Operating Margin %41.47%47.67%47.86%50.91%50.6%32.98%40.02%-12.95%49.48%47.23%66.41%47.69%41.82%26.19%46.03%42.76%27.16%7.03%-29.15%2.99%18.16%37%17.95%-21.61%-59.77%-818.93%-3977.08%-8850%-13300%
Operating Income Growth %-10.18%16.21%20.95%76.24%-6.35%416.42%-123.29%-1.17%-23.25%51.89%29.74%84.21%-30.63%32.68%93.76%530.76%131.69%-1401.86%-78.25%-32.43%224.73%214.6%35.98%61.65%42.41%-130.23%-166.17%-
EBITDA1.42B1.6B1.45B1.24B1.03B605.8M643.5M-141.7M841.3M845.9M1.09B731.94M571.04M323.76M448.79M338.32M181.93M37.4M-77.52M7.26M30.45M45.31M15.48M-9.2M-14.87M-43.42M-81.58M-36.7M-13.35M
EBITDA Margin %44.48%50.36%50.38%53.19%53.25%35.94%43.38%-9.78%51.68%49.03%68.38%49.94%44.32%28.98%48.99%45.52%30.13%10.11%-27.54%3.44%19.07%39.09%21.04%-17.25%-49.36%-757.61%-3980.97%-9175%-13346.2%
EBITDA Growth %-10.08%10.58%17.07%20.09%70.19%-5.86%554.13%-116.84%-0.54%-22.63%49.37%28.17%76.38%-27.86%32.65%85.97%386.5%148.24%-1167.77%-76.15%-32.8%192.59%268.3%38.12%65.76%46.77%-122.29%-174.98%-
D&A (Non-Cash Add-back)96M85.6M72.5M53.2M51.3M49.9M49.9M45.9M35.9M31M31.6M32.92M32.24M31.26M27.14M20.54M17.92M11.39M4.54M957K1.46M2.41M2.28M2.33M3.13M3.51M-79.74K-1.3M0
EBIT1.49B1.73B1.58B1.33B989M686.9M596.4M-120.8M802.5M1.02B1.06B1.05B542.77M292.5M457.31M320.48M174.86M31.64M-72.28M18.76M28.98M47.55M15.45M-11.53M-18M-46.94M-81.5M-35.36M-13.35M
Net Interest Income138.3M172.5M156.2M103.4M12.8M-1.9M5.1M014.7M1.9M-400K-4.7M-17.6M-14.23M-12.7M-17.92M-16.77M-7.73M-414K11.43M10.22M5.33M2.98M2.32M4.84M9.85M10.57M00
Interest Income150.2M192M199.1M162.7M45.2M16.7M28.6M44.2M28.6M10.9M3.5M003.83M3.94M3.45M2.94M5.15M11.03M13.6M10.7M5.36M2.99M2.44M4.95M10.02M10.69M00
Interest Expense11.9M19.5M42.9M59.3M32.4M18.6M23.5M44.2M13.9M9M3.9M4.74M17.59M18.06M16.64M21.37M19.71M12.88M16K2.17M482K29K4K112K117K172.72K120.03K00
Other Income/Expense185.9M196.7M162M89.4M-29.1M38M45.3M22.6M-46.5M-45.4M-1.5M345.42M-13.6M-13.6M19.02M-18.66M-16.17M-7.23M9.76M10.28M10.93M4.63M2.24M1.56M-5.65M9.65M-4.68M63.5K546.2K
Pretax Income1.51B1.71B1.54B1.27B950.6M593.9M638.9M-165M758.9M769.5M1.06B1.04B525.18M278.9M440.67M299.12M147.84M18.77M-72.3M16.58M39.91M47.52M15.45M-9.97M-23.65M-37.29M-86.18M-35.3M-12.8M
Pretax Margin %47.3%53.85%53.49%54.75%49.09%35.24%43.07%-11.39%46.62%44.6%66.31%71.26%40.76%24.97%48.1%40.25%24.48%5.07%-25.68%7.86%25%41%20.99%-18.69%-78.52%-650.55%-4205.51%-8825%-12800%
Income Tax277M379.2M343.9M289.5M223.3M118.1M124.1M-60.5M169.7M351.6M346.5M392.8M185.11M104.34M136.23M81.87M41.92M-695K-29.51M-3.28M-34.06M-17.49M000-9.65M-5.89M-1.9M0
Effective Tax Rate %18.37%22.12%22.35%22.72%23.49%19.89%19.42%36.67%22.36%45.69%32.68%37.61%35.25%37.41%30.91%27.37%28.36%-3.7%40.82%-19.76%-85.34%-36.81%0%0%0%25.88%6.84%5.38%0%
Net Income1.23B1.33B1.2B984.8M727.3M475.8M514.8M-104.5M589.2M417.9M713.7M651.64M340.07M174.56M304.44M217.87M105.92M19.46M-42.79M19.86M73.97M65.02M15.45M-9.97M-23.65M-37.29M-75.61M-33.5M-12.8M
Net Margin %38.61%41.94%41.53%42.31%37.56%28.23%34.71%-7.21%36.2%24.22%44.64%44.46%26.39%15.63%33.23%29.32%17.54%5.26%-15.2%9.41%46.33%56.09%20.99%-18.69%-78.52%-650.55%-3689.55%-8375%-12800%
Net Income Growth %-3.22%11.68%21.35%35.4%52.86%-7.58%592.63%-117.74%40.99%-41.45%9.52%91.62%94.82%-42.66%39.74%105.7%444.22%145.48%-315.46%-73.15%13.76%320.84%254.97%57.85%36.57%50.68%-125.7%-161.72%-
Net Income (Continuing)1.23B1.33B1.2B984.8M727.3M475.8M514.8M-104.5M589.2M417.9M713.7M651.64M340.07M174.56M304.44M217.24M111.21M19.46M-42.79M19.86M73.97M65.02M15.45M-9.97M-23.65M-37.29M-75.61M-33.5M-12.8M
Discontinued Operations00000000000000000000000000000
Minority Interest00000000000000000000000000000
EPS (Diluted)27.1727.8624.6419.8115.0010.0611.54-2.3913.399.3115.2512.726.283.285.713.671.780.35-0.930.441.531.290.33-0.24-0.57-0.92-1.97-1.26-0.77
EPS Growth %0.27%13.07%24.38%32.07%49.11%-12.83%582.85%-117.85%43.82%-38.95%19.89%102.55%91.46%-42.56%55.59%106.18%408.57%137.63%-311.36%-71.24%18.6%290.91%237.5%57.89%38.04%53.3%-56.35%-63.64%-
EPS (Basic)-30.1326.4421.0415.9810.6011.65-2.3913.549.5016.2914.177.063.495.843.811.890.37-0.930.471.611.430.36-0.24-0.57-0.92-1.97-1.26-0.77
Diluted Shares Outstanding45.3M47.9M48.5M49.7M48.5M47.3M44.6M43.8M44M44.9M46.8M51.22M54.16M53.23M53.28M59.4M59.52M56.13M45.8M44.9M48.28M50.41M46.7M42.27M41.29M40.57M38.47M26.69M16.64M
Basic Shares Outstanding42.7M44.3M45.2M46.8M45.5M44.9M44.2M43.8M43.5M44M43.8M46M48.18M50.08M52.09M57.16M56.14M53.31M45.8M42.45M46.02M45.65M43.45M42.27M41.29M40.57M38.47M26.69M16.64M
Dividend Payout Ratio-----------------------------

Key Metrics

Growth RegimeStable
ProfitabilityStrong
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Tyvaso generic and Winrevair competition

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Top-Line Growth Plateauing Near $800M

Based on reported quarterly figures, UTHR's revenue reached $832.5M in 2026Q3, up 4.1% year over year, a marked deceleration from the mid-teens growth rates recorded through 2024 and early 2025.

The reported figures suggest the core treprostinil franchise has matured, with quarterly revenue oscillating in a narrow $780M to $830M band since early 2025. The deceleration may reflect saturation in the nebulized Tyvaso base alongside early generic pressure on Adcirca, though the reported data does not isolate volume from pricing contributions. Investors should monitor whether PH-ILD uptake and Tyvaso DPI conversion can re-accelerate top-line growth or whether the plateau persists.

Gross Margin Holds Near 88 Percent

As reported in the income statement, UTHR's gross margin averaged roughly 87 to 89 percent across most periods, with the Q1 2026 dip to 82.9 percent standing out as the primary deviation from that range.

The consistency of gross margin around 88 percent is consistent with the pricing power typically associated with orphan-drug franchises and low marginal synthesis cost of treprostinil. The Q1 2026 compression appears linked to a sharp rise in COGS to $133.4M, which may reflect channel or royalty timing rather than a structural shift, though the filings alone do not confirm the cause. Sustained margin erosion toward the low 80s would warrant concern about generic pricing pressure.

Operating Margin Compresses From Peak

Based on reported figures, UTHR's operating margin fell from roughly 48 percent in mid-2025 to 37.0 percent in 2026Q3, as operating income declined while R&D expense rose toward $279M.

Operating income has declined from above $380M in early 2025 to $307.8M in the latest quarter, indicating negative operating leverage as revenue flattened while costs rose. R&D spending, which more than doubled sequentially in 2026Q3 relative to the prior quarter, appears to be the dominant driver of this compression. The trend suggests that near-term profitability is sensitive to the pace of pipeline investment, and investors should monitor whether R&D intensity moderates.

EPS Miss Outpaces Operating Decline

According to reported figures, UTHR's 2026Q3 diluted EPS of $5.71 declined 20.3 percent year over year, a sharper drop than the 9.9 percent decline in operating income would imply on its own.

The gap between EPS decline and operating income decline may reflect below-the-line items, tax rate changes, or share count effects, though the provided data does not itemize these. Net income of $258.6M against operating income of $307.8M implies meaningful non-operating drag in the latest quarter. Analysts should reconcile the bridge from operating to net income before drawing conclusions about underlying earnings power.

Pipeline Spend Masks Franchise Risk

The bullish management framing of extraordinary growth appears difficult to reconcile with reported revenue growth of 4.1 percent and a 20.3 percent EPS decline, suggesting the thesis depends heavily on unquantified pipeline contributions.

The strongest bear case is that rising R&D spend and the absence of quantified guidance may be deferring recognition of franchise erosion from Tyvaso generic entry and Winrevair competition. If core PAH revenue is under pressure, pipeline spending could be consuming cash that might otherwise support earnings. Investors may wish to assess whether IPF and organ manufacturing milestones are sufficiently de-risked to justify current R&D intensity, recognizing that these conclusions rely on limited disclosed data.

UTHR — Frequently Asked Questions

Quick answers to the most common questions about buying UTHR stock.

What was United Therapeutics Corporation's (UTHR) revenue in 2025?

For fiscal year 2025, United Therapeutics Corporation (UTHR) reported total revenue of $3.18B. This represents a 3182600.0% increase compared to $0.1M in 1998.

Is United Therapeutics Corporation (UTHR) profitable?

United Therapeutics Corporation (UTHR) is profitable, generating $1.33B in net income for the fiscal year ending 2025 with a net profit margin of 41.9%.

What is United Therapeutics Corporation's operating profit margin?

United Therapeutics Corporation (UTHR) reported an operating income of $1.52B, resulting in an operating profit margin of 47.7%. This margin reflects the operational efficiency of the business before interest and taxes.

What is United Therapeutics Corporation's gross profit and gross margin?

United Therapeutics Corporation (UTHR) generated $2.80B in gross profit for the year, representing a gross profit margin of 87.9%. This demonstrates the company's core pricing power and production efficiency.